Doctor consults with patient. Image credit: Canva.
Treatment plans for individuals who are diagnosed with colorectal cancer or gastroesophageal cancer often include major surgery to remove tumors from the esophagus, stomach, colon or rectum. These surgeries can negatively impact quality of life.
A clinical trial led by Nicholas D. Klemen, M.D., Physician-Scientist Early Investigator in the Surgery Branch, is researching drug therapy for adults with these cancers to see if surgery can be delayed or even avoided.
Participants with gastroesophageal cancer must also have changes in a particular gene that result in MMR deficiency.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact the NCI Cancer Information Service at 1-888-624-1937 or nciinfo@mail.nih.gov
Clinicaltrials.gov identifier: NCT06410534
NCI Protocol ID: IRB001691
Official Title: A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
